Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 24, 2017

DrugPatentWatch Database Preview

ALFUZOSIN HYDROCHLORIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Alfuzosin Hydrochloride, and when can generics launch?

Alfuzosin Hydrochloride is a drug marketed by Apotex Inc, Mylan, Wockhardt Ltd, Torrent Pharms, Teva Pharms, Sun Pharma Global, Aurobindo Pharma Ltd, Invagen Pharms, and Unichem Labs Ltd. and is included in nine NDAs.

The generic ingredient in ALFUZOSIN HYDROCHLORIDE is alfuzosin hydrochloride. There are nineteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the alfuzosin hydrochloride profile page.

Summary for Tradename: ALFUZOSIN HYDROCHLORIDE

Patents:0
Applicants:9
NDAs:9
Suppliers / Packagers: see list20
Bulk Api Vendors: see list44
Clinical Trials: see list995
Patent Applications: see list214
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ALFUZOSIN HYDROCHLORIDE at DailyMed

Pharmacology for Tradename: ALFUZOSIN HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc
ALFUZOSIN HYDROCHLORIDE
alfuzosin hydrochloride
TABLET, EXTENDED RELEASE;ORAL079013-001Jul 18, 2011ABRXNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
ALFUZOSIN HYDROCHLORIDE
alfuzosin hydrochloride
TABLET, EXTENDED RELEASE;ORAL079060-001Aug 30, 2012ABRXNoNo► Subscribe► Subscribe
Torrent Pharms
ALFUZOSIN HYDROCHLORIDE
alfuzosin hydrochloride
TABLET, EXTENDED RELEASE;ORAL079054-001Jul 18, 2011ABRXNoNo► Subscribe► Subscribe
Invagen Pharms
ALFUZOSIN HYDROCHLORIDE
alfuzosin hydrochloride
TABLET, EXTENDED RELEASE;ORAL090284-001Jan 17, 2012ABRXNoNo► Subscribe► Subscribe
Mylan
ALFUZOSIN HYDROCHLORIDE
alfuzosin hydrochloride
TABLET, EXTENDED RELEASE;ORAL079014-001Jul 18, 2011ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Uncover prior art in abandoned patent applications and expired patents
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot